We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Identifies Sudden Cardiac Death Risk

By LabMedica International staff writers
Posted on 09 Jul 2014
Print article
Image: The two step amplification process involved in Multiplex Amplification of Specific Targets for Resequencing (MASTR) assay technology (Image courtesy of Multiplicom).
Image: The two step amplification process involved in Multiplex Amplification of Specific Targets for Resequencing (MASTR) assay technology (Image courtesy of Multiplicom).
A blood test has been developed which will determine the genetic risk of Sudden Cardiac Death (SCD) which affects one in a thousand people, and it is especially healthy young individuals who are affected by SCD.

Genetic predisposition plays an important role as family members of affected individuals have a 50% risk of inheriting the same genetic predisposition to develop cardiac disease and therefore early detection of hereditary heart disease in high-risk families can save lives.

Scientists at University of Antwerp (Belgium) working with clinicians at the Antwerp University Hospital (Belgium) have been using a new molecular genetic test to determine the risk of SCD. Patients and family members are seen by a multidisciplinary team of geneticist, cardiologist and psychosocial workers. This collaboration offers the opportunity to answer both genetic and cardiological questions during the same clinic visit. Moreover, both the clinical and genetic work-up of families is streamlined to the benefit of the patient.

The genetic test is called PED MASTR (Multiplicom; Niel, Belgium) and is already in use at the center of medical genetics of the University of Antwerp and the Antwerp University Hospital and will be launched worldwide from September 2014. With the development of the PED MASTR it has become feasible and fast to fully analyze the high number of genes involved for SCD causing mutations.

Multiplicom’s Multiplex Amplification of Specific Targets for Resequencing (MASTR) assays enable multiplex polymerase chain reaction (PCR) amplification of all required coding sequences of the genes of interest in a limited number of PCR reactions. Further downstream pooling of DNA amplicons and barcoding individual samples of the MASTR assays with contemporary massive parallel sequencing (MPS) technologies, allows simple, high throughput and cost-effective sequencing for both research and diagnostic purposes.

Dirk Pollet, PhD, the CEO of Multiplicom, said, “This new kit, using our MASTR technology, comprising 51 genes, allows physicians to identify all genetic mutations at once and use this information to propose appropriate treatment. This has been a unique project, bringing together the expertise of clinicians, geneticists and diagnostic developers to deliver to society a product that will save young lives.” The clinical scientists noted that: “This test nicely complements our existing clinical cardiac- and genetic expertise and offers the option to presymptomatic but mutation-carrying individuals to implement preventive measures to avoid SCD.”

Related Links:

University of Antwerp
Antwerp University Hospital
Multiplicom


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.